Please login to the form below

Not currently logged in
Email:
Password:

Enterprise Therapeutics appoints CEO

Dr John Ford will lead the UK drug discovery company

Enterprise Therapeutics Dr John FordBrighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.

In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.

Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.

Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.

“His expertise will complement the existing team and we are thrilled to have him on board.”

3rd November 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics